Tanaka, Shota
Batchelor, Tracy T.
Iafrate, A. John
Dias-Santagata, Dora
Borger, Darrell R.
Ellisen, Leif W.
Yang, Daniel
Louis, David N.
Cahill, Daniel P.
Chi, Andrew S.
Funding for this research was provided by:
Burroughs Wellcome Fund (Career Awards for Medical Scientists)
American Brain Tumor Association (Basic Research Fellowship)
Ben and Catherine Ivy Foundation (Early Career Research Award)
Article History
Received: 21 March 2019
Accepted: 16 April 2019
First Online: 29 April 2019
Ethics approval and consent to participate
: An IRB-approved informed consent form was obtained from all individual patients included in this study.
: Not applicable.
: A.S.C. is an employee of Neon Therapeutics and has served on the advisory board of Cota Healthcare. T.T.B. received consulting honoraria from Merck, GenomiCare, NXDC, UpToDate, Inc., and Champions Biotechnology. A.J.I. received equity from ArcherDx. The other authors declare no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.